Paradigm Biopharmaceuticals (PAR) Stock Overview
Engages in the research and development of therapeutic products for human use in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
PAR Community Fair Values
Create NarrativeSee what 95 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Paradigm Biopharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.25 |
| 52 Week High | AU$0.49 |
| 52 Week Low | AU$0.24 |
| Beta | 0.18 |
| 1 Month Change | -15.25% |
| 3 Month Change | -29.58% |
| 1 Year Change | -45.65% |
| 3 Year Change | -81.75% |
| 5 Year Change | -89.36% |
| Change since IPO | -32.43% |
Recent News & Updates
Weekly Picks: 💻 A Hedge Against US Government Shutdown And 2 More Picks
Oct 21
Paradigm Biopharmaceuticals Will Lead Osteoarthritis Treatment with Zilosul's FDA Success
Paradigm Biopharmaceuticals (ASX: PAR) on Cusp of Transformation with Potential FDA Approval of Osteoarthritis Drug Zilosul® Melbourne, Australia - Paradigm Biopharmaceuticals (ASX: PAR), a late-stage drug development company, is poised at a critical juncture as it progresses its lead drug candidate, Zilosul® (injectable pentosan polysulfate sodium), through Phase 3 clinical trials for the treatment of osteoarthritis (OA). A successful outcome and subsequent clearance from the U.S. Food and Drug Administration (FDA) could unlock a multi-billion dollar market and fundamentally reshape the company's future, offering a new treatment paradigm for millions suffering from the debilitating joint disease.Recent updates
Weekly Picks: 💻 A Hedge Against US Government Shutdown And 2 More Picks
Oct 21Paradigm Biopharmaceuticals Will Lead Osteoarthritis Treatment with Zilosul's FDA Success
Paradigm Biopharmaceuticals (ASX: PAR) on Cusp of Transformation with Potential FDA Approval of Osteoarthritis Drug Zilosul® Melbourne, Australia - Paradigm Biopharmaceuticals (ASX: PAR), a late-stage drug development company, is poised at a critical juncture as it progresses its lead drug candidate, Zilosul® (injectable pentosan polysulfate sodium), through Phase 3 clinical trials for the treatment of osteoarthritis (OA). A successful outcome and subsequent clearance from the U.S. Food and Drug Administration (FDA) could unlock a multi-billion dollar market and fundamentally reshape the company's future, offering a new treatment paradigm for millions suffering from the debilitating joint disease.We're Keeping An Eye On Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Rate
Apr 22
Paradigm Biopharmaceuticals (ASX:PAR) Is In A Strong Position To Grow Its Business
Aug 22Here's Why We're Not At All Concerned With Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation
Apr 17Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth
Sep 21Here's Why We're Not Too Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation
Jun 20Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth
Dec 02Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth
Jun 07Is Paradigm Biopharmaceuticals Limited (ASX:PAR) Trading At A 46% Discount?
Feb 22We're Not Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn
Jan 24
Did You Participate In Any Of Paradigm Biopharmaceuticals' (ASX:PAR) Incredible 811% Return?
Dec 28When Will Paradigm Biopharmaceuticals Limited (ASX:PAR) Turn A Profit?
Nov 29Shareholder Returns
| PAR | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -9.1% | -3.8% | 1.4% |
| 1Y | -45.7% | -42.9% | 12.0% |
Return vs Industry: PAR underperformed the Australian Biotechs industry which returned -42.9% over the past year.
Return vs Market: PAR underperformed the Australian Market which returned 12% over the past year.
Price Volatility
| PAR volatility | |
|---|---|
| PAR Average Weekly Movement | 7.8% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 9.6% |
| 10% most volatile stocks in AU Market | 17.8% |
| 10% least volatile stocks in AU Market | 3.8% |
Stable Share Price: PAR has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: PAR's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Paul Rennie | www.paradigmbiopharma.com |
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.
Paradigm Biopharmaceuticals Limited Fundamentals Summary
| PAR fundamental statistics | |
|---|---|
| Market cap | AU$109.81m |
| Earnings (TTM) | -AU$36.09m |
| Revenue (TTM) | AU$8.45k |
Is PAR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PAR income statement (TTM) | |
|---|---|
| Revenue | AU$8.45k |
| Cost of Revenue | AU$6.38k |
| Gross Profit | AU$2.07k |
| Other Expenses | AU$36.09m |
| Earnings | -AU$36.09m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.082 |
| Gross Margin | 24.53% |
| Net Profit Margin | -427,113.40% |
| Debt/Equity Ratio | 0% |
How did PAR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/04 20:01 |
| End of Day Share Price | 2026/03/04 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Paradigm Biopharmaceuticals Limited is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Hester | Bell Potter |
| Soo Romanoff | Edison Investment Research |
| Arron Aatkar | Edison Investment Research |